Specific antibody responses against the 2 major subcomponents of EBNA, EBNAl and EBNAZ were evaluated, in order to study whether this serological study was beneficial compared to classical EBV serology. During this investigation, 491 sera, obtained from blood donors and patients with Burkitt's lymph
Antibody response against the epstein-barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma
β Scribed by Masashi Chatani; Teruki Teshima; Toshihiko Inoue; Kunitoshi Yoshino; Nobuko Ikegami; Misuzu Shimakage; Kanji Hirai
- Book ID
- 115043683
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 306 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0023-852X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract EpsteinβBarr virus nuclear antigen (EBNA) preparations from three sources were tested with sera from normal individuals and patients with Hodgkin's disease, breast carcinoma, Burkitt's lymphoma, and American and Chinese nasopharyngeal carcinoma. Individual sera with discordant antibody
## Abstract The EpsteinβBarr virus nuclear antigen I (EBNA I) is the only latent EBV antigen consistently expressed in malignant tissues of the nasopharynx. A 20βaminoβacid synthetic peptide, p107 contains a major epitope of EBNA I. We tested sera from 210 patients with nasopharyngeal carcinoma (NP
## Abstract Antibodyβdependent cellular cytotoxicity (ADCC) was performed on serum samples from African patients with nasopharyngeal carcinoma (NPC) to determine whether antibody titers determined by this assay might be of prognostic value in this disease. The serum donors were divided into two gro